PABPC1
PABPC1 (Polyadenylate-binding protein 1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Hepatocellular carcinoma, Multiple myeloma, Bladder & urothelial cancer and 5 more.
Overview
Binds the poly(A) tail of mRNA, including that of its own transcript, and regulates processes of mRNA metabolism such as pre-mRNA splicing and mRNA stability. Its function in translational initiation regulation can either be enhanced by PAIP1 or repressed by PAIP2. Can probably bind to cytoplasmic RNA sequences other than poly(A) in vivo.
Open Targets scores its association with cancer at 0.59 (direct and indirect evidence; datatypes literature 0.97, genetic association 0.00, somatic mutation 0.69). IntOGen calls it a driver in 8 cohorts (8 activating, 0 loss-of-function), covering Basal Cell Carcinoma, Diffuse Large B-Cell Lymphoma, NOS, Hepatocellular Carcinoma, Lung Squamous Cell Carcinoma, Plasma Cell Myeloma, Upper Tract Urothelial Carcinoma and others.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · PABPC1 (Polyadenylate-binding protein 1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Hepatocellular carcinoma, Multiple myeloma, Bladder & urothelial cancer and 5 more.
- 1 · What it is
PABPC1 (Polyadenylate-binding protein 1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Hepatocellular carcinoma, Multiple myeloma, Bladder & urothelial cancer and 5 more.
- 2 · What goes wrong in cancer
Binds the poly(A) tail of mRNA, including that of its own transcript, and regulates processes of mRNA metabolism such as pre-mRNA splicing and mRNA stability.
- 3 · How drugs use it
No product in this corpus aims at PABPC1 yet. Drugs fit a pocket that exists only in one shape of the mutant protein and hold it there, off.
External identifiers
Sources: HGNC HGNC:8554 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P11940 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000070756 (association with cancer (MONDO_0004992) 0.59; (GraphQL API, CC0)); IntOGen PABPC1 (driver in 8 cohorts (Act 8, LoF 0); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Binds the poly(A) tail of mRNA, including that of its own transcript, and regulates processes of mRNA metabolism such as pre-mRNA splicing and mRNA stability. Its function in translational initiation regulation can either be enhanced by PAIP1 or repressed by PAIP2. Can probably bind to cytoplasmic RNA sequences other than poly(A) in vivo. Binds to N6-methyladenosine (m6A)-containing mRNAs and contributes to MYC stability by binding to m6A-containing MYC mRNAs. Involved in translationally coupled mRNA turnover. Implicated with other RNA-binding proteins in the cytoplasmic deadenylation/translational and decay interplay of the FOS mRNA mediated by the major coding-region determinant of instability (mCRD) domain. Location: Cytoplasm; Cytoplasm, Stress granule; Nucleus; Cell projection, lamellipodium (UniProt). Locus 8q22.3 (HGNC).
- Hepatocellular carcinoma: IntOGen driver in 1 cohort (HCC)
- Multiple myeloma: IntOGen driver in 1 cohort (PCM)
- Bladder & urothelial cancer: IntOGen driver in 1 cohort (UTUC)
- Thyroid cancer: IntOGen driver in 1 cohort (WDTC)
- Diffuse large B-cell lymphoma: IntOGen driver in 2 cohorts (DLBCLNOS)
- Basal cell carcinoma: IntOGen driver in 1 cohort (BCC)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 8 cohorts. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"PABPC1" OR ABSTRACT:"PABPC1" OR TITLE:"poly A binding protein cytoplasmic 1" OR ABSTRACT:"poly A binding protein cytoplasmic 1" OR TITLE:"Polyadenylate-binding protein 1" OR ABSTRACT:"Polyadenylate-binding protein 1" OR TITLE:"PABP1" OR ABSTRACT:"PABP1" OR TITLE:"PABPL1" OR ABSTRACT:"PABPL1" OR TITLE:"PAB1" OR ABSTRACT:"PAB1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about PABPC1, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetARHGAP5
Shares Papillary thyroid cancer, Thyroid cancer, Bladder & urothelial cancer, IntOGen.
- TargetCCDC6
Shares Basal cell carcinoma, Thyroid cancer, IntOGen, Open Targets Platform.
- TargetZFHX3
Shares Thyroid cancer, Bladder & urothelial cancer, Hepatocellular carcinoma, IntOGen.
- TargetEPHA7
Shares Thyroid cancer, Hepatocellular carcinoma, IntOGen, Open Targets Platform.
- TargetAFF3
Shares Papillary thyroid cancer, Thyroid cancer, IntOGen, Open Targets Platform.
- TargetCOL2A1
Shares Papillary thyroid cancer, Thyroid cancer, IntOGen.
- TargetPICALM
Shares Papillary thyroid cancer, Thyroid cancer, IntOGen.
- TargetDGCR8
Shares Papillary thyroid cancer, Thyroid cancer, Diffuse large B-cell lymphoma, IntOGen.